Presentation

VALBIOTIS strives towards providing a new approach called “Nutrition Healthcare”:

• Prevent disease by developing innovative products that reduce the risk factors of irreversible chronic diseases;
• Provide patient support through new-generation medical nutrition solutions containing patented innovative substances with clinically proven effects.

VALBIOTIS teams have strong regulatory, scientific and clinical expertise thanks to their perfect knowledge of:

• New-generation screening techniques;
• Complete characterization of plant matter;
• Purification processes / plant fractionation;
• Pre-clinical tests at various levels: molecular, cellular, tissular, in vivo;
• Designing and managing clinical trials implemented by specialized service providers.

In order to enhance its capacity and speed of innovation and development, VALBIOTIS—since its creation—has formed several partnerships with top academic centers in France and abroad. The company’s most prominent partners, the La Rochelle University, the CNRS and the Clermont Auvergne University, work daily with VALBIOTIS teams with the same powerful ambition: achieving a “Zero Diabetes World”.

This expertise makes it possible to quickly identify biomolecules with new properties that can be patented, and to design health nutrition products.

From the screening stages, VALBIOTIS focuses its research on common food plants with the advantage of:

• Secure supplies and prices, which enable large-scale industrial production;
• Controlled toxicological risk;
• Naturalness which inspires trust.

This process enables VALBIOTIS to design safe, clinically effective patented products, within a short development period (approximately 6 years compared to an average of 12 years for one drug), with a much lower risk profile.